Detail information
ID ENOM00091
Accession GSE255952
Status Public on Feb 20, 2024
Title Transcriptome data of B cells and T helper cells from patients with multiple sclerosis receiving methylprednisolone for the treatment of an acute relapse
Organism Homo sapiens
Experiment type Expression profiling by array
Summary
We analyzed the transcriptome profiles of CD19+ B cells and CD4+ T cells from the peripheral blood of patients with multiple sclerosis (MS) immediately before and after relapse therapy with high-dose methylprednisolone (MP). High-density Clariom D Arrays for human were used to quantify the transcript levels. This GEO entry provides the processed data from the gene-level and exon-level workflows.
Samples
GSM ID Sample info Characteristics Description
GSM8083291 patient C1P1, before first course of MP, T cells tissue: peripheral blood patient id: C1P1 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: non-responder percentage in pbmc: 34.9 cells per ml: 2982000 purity (%): 98.1 rna integrity number: 7.8 age (years): 60 Sex: female body weight (in kg): 75.4 body size (in cm): 168 body mass index: 26.7 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 11 number of relapses in the past 2 years: 0 duration since last relapse (months): 133 edss score: 3.5 disease-modifying therapy: teriflunomide number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: hair loss Gene expression data for a patient with MS treated with methylprednisolone C1P1-M1-T0-CD4
GSM8083292 patient C1P1, after first course of MP, T cells tissue: peripheral blood patient id: C1P1 mp course: first time point: after cell population: CD4+ T cells clinical evaluation: non-responder percentage in pbmc: 25.9 cells per ml: 304500 purity (%): 95.3 rna integrity number: 8.7 age (years): 60 Sex: female body weight (in kg): 75.4 body size (in cm): 168 body mass index: 26.7 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 11 number of relapses in the past 2 years: 0 duration since last relapse (months): 133 edss score: NA disease-modifying therapy: teriflunomide number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: worse fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: hair loss Gene expression data for a patient with MS treated with methylprednisolone C1P1-M1-T1-CD4
GSM8083293 patient C1P1, before second course of MP, T cells tissue: peripheral blood patient id: C1P1 mp course: second time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 27.8 cells per ml: 1254750 purity (%): 96.7 rna integrity number: 8.3 age (years): 60 Sex: female body weight (in kg): 75.4 body size (in cm): 168 body mass index: 26.7 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 11 number of relapses in the past 2 years: 0 duration since last relapse (months): 134 edss score: 3.5 disease-modifying therapy: teriflunomide number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 6000 days from first to last mp application: 2 side effects to mp: headache, diarrhea Gene expression data for a patient with MS treated with methylprednisolone C1P1-M2-T0-CD4
GSM8083294 patient C1P1, after second course of MP, T cells tissue: peripheral blood patient id: C1P1 mp course: second time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 6.6 cells per ml: 231000 purity (%): 93.7 rna integrity number: 9.4 age (years): 60 Sex: female body weight (in kg): 75.4 body size (in cm): 168 body mass index: 26.7 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 11 number of relapses in the past 2 years: 0 duration since last relapse (months): 134 edss score: NA disease-modifying therapy: teriflunomide number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: worse fs: sensory: better fs: visual: unchanged total dose of mp in mg: 6000 days from first to last mp application: 2 side effects to mp: headache, diarrhea Gene expression data for a patient with MS treated with methylprednisolone C1P1-M2-T1-CD4
GSM8083295 patient C1P2, before first course of MP, B cells tissue: peripheral blood patient id: C1P2 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 4.7 cells per ml: 236250 purity (%): 91.9 rna integrity number: 9.0 age (years): 38 Sex: male body weight (in kg): 67 body size (in cm): 183 body mass index: 20.0 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 17 number of relapses in the past 2 years: 0 duration since last relapse (months): 206 edss score: 3.0 disease-modifying therapy: teriflunomide number of other medications taken: 0 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: yes fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 6 side effects to mp: none Gene expression data for a patient with MS treated with methylprednisolone C1P2-M1-T0-CD19
GSM8083296 patient C1P2, after first course of MP, B cells tissue: peripheral blood patient id: C1P2 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 3.7 cells per ml: 283500 purity (%): 91.0 rna integrity number: 9.1 age (years): 38 Sex: male body weight (in kg): 67 body size (in cm): 183 body mass index: 20.0 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 17 number of relapses in the past 2 years: 0 duration since last relapse (months): 206 edss score: 3.0 disease-modifying therapy: teriflunomide number of other medications taken: 0 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: better fs: cerebral: unchanged fs: pyramidal: better fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 6 side effects to mp: none Gene expression data for a patient with MS treated with methylprednisolone C1P2-M1-T1-CD19
GSM8083297 patient C1P2, before first course of MP, T cells tissue: peripheral blood patient id: C1P2 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 28.7 cells per ml: 693000 purity (%): 96.0 rna integrity number: 8.3 age (years): 38 Sex: male body weight (in kg): 67 body size (in cm): 183 body mass index: 20.0 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 17 number of relapses in the past 2 years: 0 duration since last relapse (months): 206 edss score: 3.0 disease-modifying therapy: teriflunomide number of other medications taken: 0 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: yes fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 6 side effects to mp: none Gene expression data for a patient with MS treated with methylprednisolone C1P2-M1-T0-CD4
GSM8083298 patient C1P2, after first course of MP, T cells tissue: peripheral blood patient id: C1P2 mp course: first time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 11.5 cells per ml: 624750 purity (%): 96.0 rna integrity number: 8.3 age (years): 38 Sex: male body weight (in kg): 67 body size (in cm): 183 body mass index: 20.0 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 17 number of relapses in the past 2 years: 0 duration since last relapse (months): 206 edss score: 3.0 disease-modifying therapy: teriflunomide number of other medications taken: 0 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: better fs: cerebral: unchanged fs: pyramidal: better fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 6 side effects to mp: none Gene expression data for a patient with MS treated with methylprednisolone C1P2-M1-T1-CD4
GSM8083299 patient C1P3, before first course of MP, B cells tissue: peripheral blood patient id: C1P3 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 10.0 cells per ml: 498750 purity (%): 98.8 rna integrity number: 8.9 age (years): 34 Sex: female body weight (in kg): 63 body size (in cm): 168 body mass index: 22.3 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 8 number of relapses in the past 2 years: 1 duration since last relapse (months): 5 edss score: 2.5 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 1 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none Gene expression data for a patient with MS treated with methylprednisolone C1P3-M1-T0-CD19
GSM8083300 patient C1P3, after first course of MP, B cells tissue: peripheral blood patient id: C1P3 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 6.7 cells per ml: 383250 purity (%): 97.9 rna integrity number: 9.4 age (years): 34 Sex: female body weight (in kg): 63 body size (in cm): 168 body mass index: 22.3 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 8 number of relapses in the past 2 years: 1 duration since last relapse (months): 5 edss score: 2.5 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 1 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none Gene expression data for a patient with MS treated with methylprednisolone C1P3-M1-T1-CD19
GSM8083301 patient C1P3, before first course of MP, T cells tissue: peripheral blood patient id: C1P3 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 31.0 cells per ml: 1134000 purity (%): 94.7 rna integrity number: 8.1 age (years): 34 Sex: female body weight (in kg): 63 body size (in cm): 168 body mass index: 22.3 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 8 number of relapses in the past 2 years: 1 duration since last relapse (months): 5 edss score: 2.5 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 1 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none Gene expression data for a patient with MS treated with methylprednisolone C1P3-M1-T0-CD4
GSM8083302 patient C1P3, after first course of MP, T cells tissue: peripheral blood patient id: C1P3 mp course: first time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 18.1 cells per ml: 640500 purity (%): 96.2 rna integrity number: 8.1 age (years): 34 Sex: female body weight (in kg): 63 body size (in cm): 168 body mass index: 22.3 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 8 number of relapses in the past 2 years: 1 duration since last relapse (months): 5 edss score: 2.5 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 1 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none Gene expression data for a patient with MS treated with methylprednisolone C1P3-M1-T1-CD4
GSM8083303 patient C1P3, before second course of MP, T cells tissue: peripheral blood patient id: C1P3 mp course: second time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 30.3 cells per ml: 897750 purity (%): 97.0 rna integrity number: 8.5 age (years): 34 Sex: female body weight (in kg): 63 body size (in cm): 168 body mass index: 22.3 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 8 number of relapses in the past 2 years: 1 duration since last relapse (months): 5 edss score: 2.5 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 1 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 6000 days from first to last mp Gene expression data for a patient with MS treated with methylprednisolone C1P3-M2-T0-CD4
GSM8083304 patient C1P3, after second course of MP, T cells tissue: peripheral blood patient id: C1P3 mp course: second time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 27.7 cells per ml: 1433250 purity (%): 97.5 rna integrity number: 8.3 age (years): 34 Sex: female body weight (in kg): 63 body size (in cm): 168 body mass index: 22.3 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 8 number of relapses in the past 2 years: 1 duration since last relapse (months): 5 edss score: 2.5 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 1 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: unchanged total dose of mp in mg: 6000 days from first to last mp application: 5 side effects to mp: none Gene expression data for a patient with MS treated with methylprednisolone C1P3-M2-T1-CD4
GSM8083305 patient C1P4, before first course of MP, B cells tissue: peripheral blood patient id: C1P4 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 7.3 cells per ml: 378000 purity (%): 96.3 rna integrity number: 9.6 age (years): 53 Sex: female body weight (in kg): 58 body size (in cm): 159 body mass index: 22.9 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 3 number of relapses in the past 2 years: 0 duration since last relapse (months): 34 edss score: 3.0 disease-modifying therapy: glatiramer acetate number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none Gene expression data for a patient with MS treated with methylprednisolone C1P4-M1-T0-CD19
GSM8083306 patient C1P4, after first course of MP, B cells tissue: peripheral blood patient id: C1P4 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 7.5 cells per ml: 939750 purity (%): 96.7 rna integrity number: 8.8 age (years): 53 Sex: female body weight (in kg): 58 body size (in cm): 159 body mass index: 22.9 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 3 number of relapses in the past 2 years: 0 duration since last relapse (months): 34 edss score: NA disease-modifying therapy: glatiramer acetate number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none Gene expression data for a patient with MS treated with methylprednisolone C1P4-M1-T1-CD19
GSM8083307 patient C1P4, before first course of MP, T cells tissue: peripheral blood patient id: C1P4 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 38.1 cells per ml: 1522500 purity (%): 98.7 rna integrity number: NA age (years): 53 Sex: female body weight (in kg): 58 body size (in cm): 159 body mass index: 22.9 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 3 number of relapses in the past 2 years: 0 duration since last relapse (months): 34 edss score: 3.0 disease-modifying therapy: glatiramer acetate number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none Gene expression data for a patient with MS treated with methylprednisolone C1P4-M1-T0-CD4
GSM8083308 patient C1P4, after first course of MP, T cells tissue: peripheral blood patient id: C1P4 mp course: first time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 15.9 cells per ml: 1617000 purity (%): 98.3 rna integrity number: 8.5 age (years): 53 Sex: female body weight (in kg): 58 body size (in cm): 159 body mass index: 22.9 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 3 number of relapses in the past 2 years: 0 duration since last relapse (months): 34 edss score: NA disease-modifying therapy: glatiramer acetate number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none Gene expression data for a patient with MS treated with methylprednisolone C1P4-M1-T1-CD4
GSM8083309 patient C1P5, before first course of MP, T cells tissue: peripheral blood patient id: C1P5 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: non-responder percentage in pbmc: 31.6 cells per ml: 1344000 purity (%): 99.1 rna integrity number: 8.0 age (years): 42 Sex: male body weight (in kg): 57 body size (in cm): 180 body mass index: 17.6 current smoker: yes study center: Berlin course of disease: CIS/RRMS disease duration (years): 16 number of relapses in the past 2 years: 2 duration since last relapse (months): NA edss score: 7.5 disease-modifying therapy: ocrelizumab number of other medications taken: 6 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: no fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 5 side effects to mp: none Gene expression data for a patient with MS treated with methylprednisolone C1P5-M1-T0-CD4
GSM8083310 patient C1P5, after first course of MP, T cells tissue: peripheral blood patient id: C1P5 mp course: first time point: after cell population: CD4+ T cells clinical evaluation: non-responder percentage in pbmc: 21.9 cells per ml: 1165500 purity (%): 98.9 rna integrity number: 8.4 age (years): 42 Sex: male body weight (in kg): 57 body size (in cm): 180 body mass index: 17.6 current smoker: yes study center: Berlin course of disease: CIS/RRMS disease duration (years): 16 number of relapses in the past 2 years: 2 duration since last relapse (months): NA edss score: 7.5 disease-modifying therapy: ocrelizumab number of other medications taken: 6 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 5 side effects to mp: none Gene expression data for a patient with MS treated with methylprednisolone C1P5-M1-T1-CD4
GSM8083311 patient C1P5, before second course of MP, T cells tissue: peripheral blood patient id: C1P5 mp course: second time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 26.9 cells per ml: 1233750 purity (%): 97.8 rna integrity number: 8.5 age (years): 42 Sex: male body weight (in kg): 57 body size (in cm): 180 body mass index: 17.6 current smoker: yes study center: Berlin course of disease: CIS/RRMS disease duration (years): 16 number of relapses in the past 2 years: 2 duration since last relapse (months): NA edss score: 7.5 disease-modifying therapy: ocrelizumab number of other medications taken: 6 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: no fs: visual: no total dose of mp in mg: 4000 days from first to last mp application: 2 side effects to mp: cardiovascular problems Gene expression data for a patient with MS treated with methylprednisolone C1P5-M2-T0-CD4
GSM8083312 patient C1P5, after second course of MP, T cells tissue: peripheral blood patient id: C1P5 mp course: second time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 11.0 cells per ml: 514500 purity (%): 98.6 rna integrity number: 8.7 age (years): 42 Sex: male body weight (in kg): 57 body size (in cm): 180 body mass index: 17.6 current smoker: yes study center: Berlin course of disease: CIS/RRMS disease duration (years): 16 number of relapses in the past 2 years: 2 duration since last relapse (months): NA edss score: 7.5 disease-modifying therapy: ocrelizumab number of other medications taken: 6 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 4000 days from first to last mp application: 2 side effects to mp: cardiovascular problems Gene expression data for a patient with MS treated with methylprednisolone C1P5-M2-T1-CD4
GSM8083313 patient C2P1, before first course of MP, B cells tissue: peripheral blood patient id: C2P1 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 11.7 cells per ml: 2604000 purity (%): 96.7 rna integrity number: 8.5 age (years): 24 Sex: female body weight (in kg): 60 body size (in cm): 170 body mass index: 20.8 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 1 duration since last relapse (months): 6 edss score: 3.0 disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none Gene expression data for a patient with MS treated with methylprednisolone C2P1-M1-T0-CD19
GSM8083314 patient C2P1, after first course of MP, B cells tissue: peripheral blood patient id: C2P1 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 8.8 cells per ml: 630000 purity (%): 97.4 rna integrity number: 8.4 age (years): 24 Sex: female body weight (in kg): 60 body size (in cm): 170 body mass index: 20.8 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 1 duration since last relapse (months): 6 edss score: NA disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none Gene expression data for a patient with MS treated with methylprednisolone C2P1-M1-T1-CD19
GSM8083315 patient C2P1, before first course of MP, T cells tissue: peripheral blood patient id: C2P1 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 41.5 cells per ml: 2436000 purity (%): 94.6 rna integrity number: 8.0 age (years): 24 Sex: female body weight (in kg): 60 body size (in cm): 170 body mass index: 20.8 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 1 duration since last relapse (months): 6 edss score: 3.0 disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none Gene expression data for a patient with MS treated with methylprednisolone C2P1-M1-T0-CD4
GSM8083316 patient C2P1, after first course of MP, T cells tissue: peripheral blood patient id: C2P1 mp course: first time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 6.2 cells per ml: 346500 purity (%): 86.5 rna integrity number: 8.0 age (years): 24 Sex: female body weight (in kg): 60 body size (in cm): 170 body mass index: 20.8 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 1 duration since last relapse (months): 6 edss score: NA disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none Gene expression data for a patient with MS treated with methylprednisolone C2P1-M1-T1-CD4
GSM8083317 patient C2P2, before first course of MP, B cells tissue: peripheral blood patient id: C2P2 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 0.9 cells per ml: 467250 purity (%): 87.3 rna integrity number: 8.8 age (years): 41 Sex: female body weight (in kg): 71 body size (in cm): 170 body mass index: 24.6 current smoker: no study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 3 duration since last relapse (months): 3 edss score: NA disease-modifying therapy: glatiramer acetate number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none Gene expression data for a patient with MS treated with methylprednisolone C2P2-M1-T0-CD19
GSM8083318 patient C2P2, after first course of MP, B cells tissue: peripheral blood patient id: C2P2 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 6.3 cells per ml: 199500 purity (%): 97.6 rna integrity number: 9.5 age (years): 41 Sex: female body weight (in kg): 71 body size (in cm): 170 body mass index: 24.6 current smoker: no study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 3 duration since last relapse (months): 3 edss score: 1.5 disease-modifying therapy: glatiramer acetate number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none Gene expression data for a patient with MS treated with methylprednisolone C2P2-M1-T1-CD19
GSM8083319 patient C2P3, before first course of MP, B cells tissue: peripheral blood patient id: C2P3 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 12.2 cells per ml: 1170750 purity (%): 97.2 rna integrity number: 8.5 age (years): 20 Sex: female body weight (in kg): 55 body size (in cm): 165 body mass index: 20.2 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 6 number of relapses in the past 2 years: 0 duration since last relapse (months): NA edss score: 1.5 disease-modifying therapy: natalizumab number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none Gene expression data for a patient with MS treated with methylprednisolone C2P3-M1-T0-CD19
GSM8083320 patient C2P3, after first course of MP, B cells tissue: peripheral blood patient id: C2P3 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 12.2 cells per ml: 1170750 purity (%): 97.2 rna integrity number: 8.5 age (years): 20 Sex: female body weight (in kg): 55 body size (in cm): 165 body mass index: 20.2 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 6 number of relapses in the past 2 years: 0 duration since last relapse (months): NA edss score: 1.5 disease-modifying therapy: natalizumab number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none
GSM8083321 patient C2P3, before first course of MP, T cells tissue: peripheral blood patient id: C2P3 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 20.2 cells per ml: 1711500 purity (%): 94.3 rna integrity number: 7.3 age (years): 20 Sex: female body weight (in kg): 55 body size (in cm): 165 body mass index: 20.2 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 6 number of relapses in the past 2 years: 0 duration since last relapse (months): NA edss score: 1.5 disease-modifying therapy: natalizumab number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none Gene expression data for a patient with MS treated with methylprednisolone C2P3-M1-T1-CD19
GSM8083322 patient C2P3, after first course of MP, T cells tissue: peripheral blood patient id: C2P3 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 22.8 cells per ml: 992250 purity (%): 96.5 rna integrity number: 8.2 age (years): 20 Sex: female body weight (in kg): 55 body size (in cm): 165 body mass index: 20.2 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 6 number of relapses in the past 2 years: 0 duration since last relapse (months): NA edss score: 1.5 disease-modifying therapy: natalizumab number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none Gene expression data for a patient with MS treated with methylprednisolone C2P3-M1-T0-CD4
GSM8083323 patient C2P4, before first course of MP, B cells tissue: peripheral blood patient id: C2P4 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: non-responder percentage in pbmc: 8.0 cells per ml: 1690500 purity (%): 96.3 rna integrity number: 9.0 age (years): 60 Sex: male body weight (in kg): 97 body size (in cm): 170 body mass index: 33.6 current smoker: no study center: Greifswald course of disease: CIS/RRMS disease duration (years): 7 number of relapses in the past 2 years: 1 duration since last relapse (months): 10 edss score: 2.0 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 8 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: yes fs: pyramidal: no fs: sensory: no fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none Gene expression data for a patient with MS treated with methylprednisolone C2P4-M1-T0-CD19
GSM8083324 patient C2P4, after first course of MP, B cells tissue: peripheral blood patient id: C2P4 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: non-responder percentage in pbmc: 2.2 cells per ml: 273000 purity (%): 93.0 rna integrity number: 8.3 age (years): 60 Sex: male body weight (in kg): 97 body size (in cm): 170 body mass index: 33.6 current smoker: no study center: Greifswald course of disease: CIS/RRMS disease duration (years): 7 number of relapses in the past 2 years: 1 duration since last relapse (months): 10 edss score: 2.0 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 8 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none Gene expression data for a patient with MS treated with methylprednisolone C2P4-M1-T1-CD19
GSM8083325 patient C2P5, before first course of MP, B cells tissue: peripheral blood patient id: C2P5 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 2.6 cells per ml: 136500 purity (%): 53.8 rna integrity number: 6.9 age (years): 59 Sex: female body weight (in kg): 60 body size (in cm): 172 body mass index: 20.3 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 4 number of relapses in the past 2 years: 1 duration since last relapse (months): 22 edss score: 3.0 disease-modifying therapy: none number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none Gene expression data for a patient with MS treated with methylprednisolone C2P5-M1-T0-CD19
GSM8083326 patient C2P5, after first course of MP, B cells tissue: peripheral blood patient id: C2P5 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 6.8 cells per ml: 687750 purity (%): 98.1 rna integrity number: 8.2 age (years): 59 Sex: female body weight (in kg): 60 body size (in cm): 172 body mass index: 20.3 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 4 number of relapses in the past 2 years: 1 duration since last relapse (months): 22 edss score: 2.0 disease-modifying therapy: none number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none Gene expression data for a patient with MS treated with methylprednisolone C2P5-M1-T1-CD19
GSM8083327 patient C2P6, before first course of MP, B cells tissue: peripheral blood patient id: C2P6 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: non-responder percentage in pbmc: 4.2 cells per ml: 546000 purity (%): 92.4 rna integrity number: 8.8 age (years): 39 Sex: female body weight (in kg): 54 body size (in cm): 164 body mass index: 20.1 current smoker: no study center: Greifswald course of disease: CIS/RRMS disease duration (years): 18 number of relapses in the past 2 years: 0 duration since last relapse (months): 47 edss score: 6.5 disease-modifying therapy: dimethyl fumarate number of other medications taken: 3 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: no fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none Gene expression data for a patient with MS treated with methylprednisolone C2P6-M1-T0-CD19
GSM8083328 patient C2P6, after first course of MP, B cells tissue: peripheral blood patient id: C2P6 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: non-responder percentage in pbmc: 6.6 cells per ml: 714000 purity (%): 97.8 rna integrity number: 9.0 age (years): 39 Sex: female body weight (in kg): 54 body size (in cm): 164 body mass index: 20.1 current smoker: no study center: Greifswald course of disease: CIS/RRMS disease duration (years): 18 number of relapses in the past 2 years: 0 duration since last relapse (months): 47 edss score: NA disease-modifying therapy: dimethyl fumarate number of other medications taken: 3 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none Gene expression data for a patient with MS treated with methylprednisolone C2P6-M1-T1-CD19
GSM8083329 patient C2P7, before first course of MP, B cells tissue: peripheral blood patient id: C2P7 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 2.7 cells per ml: 215250 purity (%): 95.6 rna integrity number: 7.8 age (years): 36 Sex: male body weight (in kg): 90 body size (in cm): NA body mass index: NA current smoker: NA study center: Greifswald course of disease: CIS/RRMS disease duration (years): 16 number of relapses in the past 2 years: 1 duration since last relapse (months): 21 edss score: 3.0 disease-modifying therapy: none number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: yes fs: cerebellar: no fs: cerebral: yes fs: pyramidal: no fs: sensory: no fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 2 side effects to mp: none Gene expression data for a patient with MS treated with methylprednisolone C2P7-M1-T0-CD19
GSM8083330 patient C2P7, after first course of MP, B cells tissue: peripheral blood patient id: C2P7 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 2.8 cells per ml: 162750 purity (%): 93.2 rna integrity number: 7.8 age (years): 36 Sex: male body weight (in kg): 90 body size (in cm): NA body mass index: NA current smoker: NA study center: Greifswald course of disease: CIS/RRMS disease duration (years): 16 number of relapses in the past 2 years: 1 duration since last relapse (months): 21 edss score: 3.0 disease-modifying therapy: none number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: better fs: pyramidal: unchanged fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 2 side effects to mp: none Gene expression data for a patient with MS treated with methylprednisolone C2P7-M1-T1-CD19
GSM8083331 patient C2P8, before first course of MP, B cells tissue: peripheral blood patient id: C2P8 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: non-responder percentage in pbmc: 3.5 cells per ml: 220500 purity (%): 95.5 rna integrity number: 8.5 age (years): 23 Sex: female body weight (in kg): NA body size (in cm): NA body mass index: NA current smoker: NA study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 1 duration since last relapse (months): 10 edss score: 2.0 disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none Gene expression data for a patient with MS treated with methylprednisolone C2P8-M1-T0-CD19
GSM8083332 patient C2P8, after first course of MP, B cells tissue: peripheral blood patient id: C2P8 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: non-responder percentage in pbmc: 11.0 cells per ml: 535500 purity (%): 97.3 rna integrity number: 7.5 age (years): 23 Sex: female body weight (in kg): NA body size (in cm): NA body mass index: NA current smoker: NA study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 1 duration since last relapse (months): 10 edss score: NA disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none Gene expression data for a patient with MS treated with methylprednisolone C2P8-M1-T1-CD19
GSM8083333 patient C3P1, before second course of MP, T cells tissue: peripheral blood patient id: C3P1 mp course: second time point: before cell population: CD4+ T cells clinical evaluation: non-responder percentage in pbmc: 24.0 cells per ml: 225750 purity (%): 97.0 rna integrity number: 7.9 age (years): 36 Sex: female body weight (in kg): 63 body size (in cm): 175 body mass index: 20.6 current smoker: yes study center: Jena course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 2 duration since last relapse (months): NA edss score: 2.5 disease-modifying therapy: dimethyl fumarate number of other medications taken: 0 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: yes total dose of mp in mg: 10000 days from first to last mp application: 6 side effects to mp: none Gene expression data for a patient with MS treated with methylprednisolone C3P1-M2-T0-CD4
GSM8083334 patient C3P1, after second course of MP, T cells tissue: peripheral blood patient id: C3P1 mp course: second time point: after cell population: CD4+ T cells clinical evaluation: non-responder percentage in pbmc: 10.1 cells per ml: 315000 purity (%): 98.6 rna integrity number: 8.3 age (years): 36 Sex: female body weight (in kg): 63 body size (in cm): 175 body mass index: 20.6 current smoker: yes study center: Jena course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 2 duration since last relapse (months): NA edss score: 2.5 disease-modifying therapy: dimethyl fumarate number of other medications taken: 0 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: worse total dose of mp in mg: 10000 days from first to last mp application: 6 side effects to mp: none Gene expression data for a patient with MS treated with methylprednisolone C3P1-M2-T1-CD4
GSM8083335 patient C4P1, before first course of MP, B cells tissue: peripheral blood patient id: C4P1 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 5.3 cells per ml: 336000 purity (%): 96.3 rna integrity number: 9.4 age (years): 45 Sex: male body weight (in kg): 90 body size (in cm): 180 body mass index: 27.8 current smoker: yes study center: Rostock course of disease: CIS/RRMS disease duration (years): 13 number of relapses in the past 2 years: 0 duration since last relapse (months): 166 edss score: 3.5 disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 5 side effects to mp: hyperhidrosis Gene expression data for a patient with MS treated with methylprednisolone C4P1-M1-T0-CD19
GSM8083336 patient C4P1, after first course of MP, B cells tissue: peripheral blood patient id: C4P1 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 6.9 cells per ml: 1417500 purity (%): 96.1 rna integrity number: 8.7 age (years): 45 Sex: male body weight (in kg): 90 body size (in cm): 180 body mass index: 27.8 current smoker: yes study center: Rostock course of disease: CIS/RRMS disease duration (years): 13 number of relapses in the past 2 years: 0 duration since last relapse (months): 166 edss score: 3.5 disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 5 side effects to mp: hyperhidrosis Gene expression data for a patient with MS treated with methylprednisolone C4P1-M1-T1-CD19
GSM8083337 patient C4P2, before first course of MP, B cells tissue: peripheral blood patient id: C4P2 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: NA cells per ml: 493500 purity (%): 94.2 rna integrity number: 8.2 age (years): 54 Sex: female body weight (in kg): 93 body size (in cm): 173 body mass index: 31.1 current smoker: no study center: Rostock course of disease: SPMS disease duration (years): 20 number of relapses in the past 2 years: 1 duration since last relapse (months): 11 edss score: 7.5 disease-modifying therapy: none number of other medications taken: 3 neurological dysfunction: NA fs: bladder or bowel: yes fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: no fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 6 side effects to mp: none Gene expression data for a patient with MS treated with methylprednisolone C4P2-M1-T0-CD19
GSM8083338 patient C4P2, after first course of MP, B cells tissue: peripheral blood patient id: C4P2 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 0.4 cells per ml: 236250 purity (%): 42.7 rna integrity number: 8.1 age (years): 54 Sex: female body weight (in kg): 93 body size (in cm): 173 body mass index: 31.1 current smoker: no study center: Rostock course of disease: SPMS disease duration (years): 20 number of relapses in the past 2 years: 1 duration since last relapse (months): 11 edss score: 6.5 disease-modifying therapy: none number of other medications taken: 3 neurological dysfunction: NA fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 6 side effects to mp: none Gene expression data for a patient with MS treated with methylprednisolone C4P2-M1-T1-CD19
Platform GPL23126: [Clariom_D_Human] Affymetrix Human Clariom D Assay [transcript (gene) version]
Indicator
AZU1, ELANE, MPO, MS4A1, CD4, AREG, ATP1B3, BCL2L11, CCNH, CH25H, CLEC4E, DDIT4, ELL2, FAM111B, FILIP1L, GAB1, IFI44L, IL1R2, JADE3, LRRC16A
MAP2K1, MIR5690, MT2A, NETO1, NR4A3, PLK2, PTGER4, RGS1, SESN1, SGK1, SLC19A2, SPRY1, THBS1, TLE1, TNFSF8, TSPYL2, WEE1, ZBTB16, AREG, AZU1
DEFA4, ELANE, EPGN, MPO, MYB, RGS1, RNASE2, S100A8, S100A9, AIM1, CASS4, CCNH, CD24, CD38, CH25H, CHI3L2, CHKA, CLC, ELL2, ERRFI1
GADD45A, GIMAP7, GRASP, IFI44L, IFI6, IL16, LINC00239, LTB, NFIL3, NR4A2, NR4A3, NUAK2
Download Download data in GEO database